Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Liz Bhatt becomes COO at Septerna

Plus new CBO, chief HR officer and head of regulatory at Prime, and SVP hires at CBM

July 28, 2022 10:15 PM UTC

Third Rock’s Septerna Inc. hired Liz Bhatt as COO and Ran Xiao as VP of finance and business operations. Bhatt was chief business & strategy officer of Applied Molecular Transport Inc. (NASDAQ:AMTI) and COO of Achaogen Inc., and worked at Gilead Sciences Inc. (NASDAQ:GILD) for a decade. Xiao was VP of finance and corporate controller at Ambys Medicines Inc., and corporate controller at Corvus Pharmaceuticals Inc. (NASDAQ:CRVS). Building on the research of GPCR pioneer Robert Lefkowitz, Septerna launched in January with a $100 million series A round led by Third Rock and a platform that modernizes GPCR drug discovery.

Prime Medicine Inc. hired Richard Brudnick as CBO, Niamh Alix as chief HR officer and Fubao Wang as SVP, head of regulatory. Brudnick was CBO and head of strategy at Codiak BioSciences Inc. (NASDAQ:CDAK); Alix was VP of global talent and HR business partner at Orchard Therapeutics plc (NASDAQ:ORTX); and Wang was VP, head of regulatory affairs at Asklepios BioPharmaceutical Inc. Prime is developing one-time prime editing gene therapies for a spectrum of diseases. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article